Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities
Acute lymphoblastic leukemia (ALL) is the most common cancer in children and one of the success stories in cancer therapeutics. Risk-directed therapy based on clinical, biologic and genetic features has played a significant role in this accomplishment. Despite the observed improvement in survival ra...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/17/2748 |
| _version_ | 1797582680675581952 |
|---|---|
| author | Maria Kourti Michalis Aivaliotis Emmanouel Hatzipantelis |
| author_facet | Maria Kourti Michalis Aivaliotis Emmanouel Hatzipantelis |
| author_sort | Maria Kourti |
| collection | DOAJ |
| description | Acute lymphoblastic leukemia (ALL) is the most common cancer in children and one of the success stories in cancer therapeutics. Risk-directed therapy based on clinical, biologic and genetic features has played a significant role in this accomplishment. Despite the observed improvement in survival rates, leukemia remains one of the leading causes of cancer-related deaths. Implementation of next-generation genomic and transcriptomic sequencing tools has illustrated the genomic landscape of ALL. However, the underlying dynamic changes at protein level still remain a challenge. Proteomics is a cutting-edge technology aimed at deciphering the mechanisms, pathways, and the degree to which the proteome impacts leukemia subtypes. Advances in mass spectrometry enable high-throughput collection of global proteomic profiles, representing an opportunity to unveil new biological markers and druggable targets. The purpose of this narrative review article is to provide a comprehensive overview of studies that have utilized applications of proteomics in an attempt to gain insight into the pathogenesis and identification of biomarkers in childhood ALL. |
| first_indexed | 2024-03-10T23:25:56Z |
| format | Article |
| id | doaj.art-9c657c8908e94d3f89523f870ce8720b |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T23:25:56Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-9c657c8908e94d3f89523f870ce8720b2023-11-19T07:59:03ZengMDPI AGDiagnostics2075-44182023-08-011317274810.3390/diagnostics13172748Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and OpportunitiesMaria Kourti0Michalis Aivaliotis1Emmanouel Hatzipantelis2Third Department of Pediatrics, School of Medicine, Aristotle University and Hippokration General Hospital, 54642 Thessaloniki, GreeceLaboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceChildren & Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceAcute lymphoblastic leukemia (ALL) is the most common cancer in children and one of the success stories in cancer therapeutics. Risk-directed therapy based on clinical, biologic and genetic features has played a significant role in this accomplishment. Despite the observed improvement in survival rates, leukemia remains one of the leading causes of cancer-related deaths. Implementation of next-generation genomic and transcriptomic sequencing tools has illustrated the genomic landscape of ALL. However, the underlying dynamic changes at protein level still remain a challenge. Proteomics is a cutting-edge technology aimed at deciphering the mechanisms, pathways, and the degree to which the proteome impacts leukemia subtypes. Advances in mass spectrometry enable high-throughput collection of global proteomic profiles, representing an opportunity to unveil new biological markers and druggable targets. The purpose of this narrative review article is to provide a comprehensive overview of studies that have utilized applications of proteomics in an attempt to gain insight into the pathogenesis and identification of biomarkers in childhood ALL.https://www.mdpi.com/2075-4418/13/17/2748acute lymphoblastic leukemiaproteomicsbiomarkers |
| spellingShingle | Maria Kourti Michalis Aivaliotis Emmanouel Hatzipantelis Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities Diagnostics acute lymphoblastic leukemia proteomics biomarkers |
| title | Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities |
| title_full | Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities |
| title_fullStr | Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities |
| title_full_unstemmed | Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities |
| title_short | Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities |
| title_sort | proteomics in childhood acute lymphoblastic leukemia challenges and opportunities |
| topic | acute lymphoblastic leukemia proteomics biomarkers |
| url | https://www.mdpi.com/2075-4418/13/17/2748 |
| work_keys_str_mv | AT mariakourti proteomicsinchildhoodacutelymphoblasticleukemiachallengesandopportunities AT michalisaivaliotis proteomicsinchildhoodacutelymphoblasticleukemiachallengesandopportunities AT emmanouelhatzipantelis proteomicsinchildhoodacutelymphoblasticleukemiachallengesandopportunities |